226,274 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Purchased by Quantbot Technologies LP

Quantbot Technologies LP bought a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 226,274 shares of the company's stock, valued at approximately $4,987,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. FMR LLC grew its holdings in shares of Teva Pharmaceutical Industries by 49.5% in the third quarter. FMR LLC now owns 62,740,763 shares of the company's stock worth $1,130,589,000 after acquiring an additional 20,762,226 shares during the period. Janus Henderson Group PLC grew its stake in shares of Teva Pharmaceutical Industries by 7,945.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company's stock valued at $86,350,000 after purchasing an additional 4,732,374 shares during the period. Clal Insurance Enterprises Holdings Ltd grew its stake in shares of Teva Pharmaceutical Industries by 12.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock valued at $859,935,000 after purchasing an additional 4,418,961 shares during the period. Todd Asset Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at about $58,243,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Teva Pharmaceutical Industries by 237.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,377,517 shares of the company's stock worth $60,863,000 after purchasing an additional 2,376,668 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insiders Place Their Bets

In related news, Director Roberto Mignone sold 286,000 shares of the firm's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the transaction, the director now directly owns 695,000 shares of the company's stock, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.55% of the company's stock.

Wall Street Analyst Weigh In

TEVA has been the subject of several analyst reports. UBS Group reduced their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. StockNews.com cut Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Friday, March 7th. Piper Sandler increased their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. Barclays lowered their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. Finally, Bank of America reduced their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $23.43.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock traded down $0.40 during mid-day trading on Tuesday, hitting $16.32. The company had a trading volume of 3,419,986 shares, compared to its average volume of 9,360,355. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The stock's 50 day moving average price is $18.19 and its 200-day moving average price is $18.28. Teva Pharmaceutical Industries Limited has a 52-week low of $12.51 and a 52-week high of $22.80. The company has a market capitalization of $18.50 billion, a P/E ratio of -11.22, a P/E/G ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.